文 献 1） 国立研究開発法人国立がん研究センター．最新がん統計. [https://ganjoho.jp/reg_stat/statistics/stat/summary.html (accessed 2025-10-25)] 2） Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Voge A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NE JM Evid 2022; 1: EVIDoa2200015. 3） 大塚将之（編）．胆道癌診療ガイドライン改訂第4版． 4） Ramai D, Maida M, Smith ER, Wang Y, Spadaccini M, Previtera M, et al. Endoluminal radiofrequency ablation with stenting versus stenting alone in patients with malignant biliary obstruction: a meta-analysis of randomized trials. Endoscopy 2025; 57: 272-81. 5） Xiao T, Hu S, Dong S, Cai Q, Gong W, Zhang Y, et al. A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma. Int Immunopharmacol 2024; 134: 112144. 6） Gao DJ, Yang JF, Ma SR, Wu J, Wang TT, Jin HB, et al. Endoscopic radiofrequency ablation plus plastic stent placement versus stent placement alone for unresectable extrahepatic biliary cancer: a multicenter randomized controlled trial. Gastrointest Endosc 2021; 94: 91-100. 7） Liang J, Ma M, Feng W, Xu Q, Chen D, Lai J, et al. Anti-PD-L1 blockade facilitates antitumor effects of radiofrequency ablation by improving tumor immune microenvironment in hepatocellular carcinoma. Apoptosis 2025; 30: 55-68. 8） Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol 2024; 35: 902-13.医学図書出版株式会社、2025.切除不能胆道癌に対するラジオ波焼灼療法とデュルバルマブ併用治療の安全性と有効性77
元のページ ../index.html#93